Protara Therapeutics (TARA) Non-Current Assets (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Non-Current Assets data on file, last reported at $51.9 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 23.55% year-over-year to $51.9 million in Q1 2026; TTM through Mar 2026 was $142.7 million, a 104.57% increase from a year earlier, with the FY2025 full-year figure at $50.0 million, up 437.31% from the prior year.
• Non-Current Assets for Q1 2026 stood at $51.9 million, up from $50.0 million in the prior quarter.
• Over the last five years, Non-Current Assets for TARA reached as high as $70.6 million in Q1 2022 and fell as low as $9.0 million in Q3 2025.
• Historically, Non-Current Assets has averaged $27.5 million across 5 years, with a median of $11.8 million in 2023.
• Across the five-year window, Non-Current Assets slumped 83.29% in 2023 and soared 437.31% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $27.1 million in 2022, then plunged by 62.24% to $10.2 million in 2023, then retreated by 9.27% to $9.3 million in 2024, then surged by 437.31% to $50.0 million in 2025, then increased by 3.93% to $51.9 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $51.9 million in Q1 2026, $50.0 million in Q4 2025, and $9.0 million in Q3 2025.